Oaktree Capital urges UK's Indivior to refresh board
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2024
0mins
Source: Reuters
Oaktree Capital Management's Request: Oaktree Capital, now Indivior's second largest shareholder, has urged the British drugmaker to refresh its board following profit warnings and declining sales of its opioid treatment, Sublocade, due to competition from Brixadi.
Impact on Indivior's Shares: Indivior's shares have dropped approximately 40% this year, exacerbated by a recent $86 million settlement related to its role in the opioid crisis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
